Therapeutic | Relatlimab |
Target | LAG3 |
Heavy Chain | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSS |
Light Chain | EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (June '19) | Phase-II/III |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2018 |
INN Year Recommended | 2019 |
Companies Involved | Bristol-Myers Squibb, Ono Pharmaceutical, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Conditions Approved | na |
Conditions Active | Malignant melanoma, Colorectal cancer, Gastric cancer, Renal cell carcinoma, Solid tumours, Oesophageal cancer, Glioblastoma |
Conditions Discontinued | Chronic lymphocytic leukaemia, Diffuse large B cell lymphoma, Hodgkin's disease, Mantle-cell lymphoma, Non-Hodgkin's lymphoma |
Notes |